The agreement builds on Silence Therapeutics’s leading expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology.
As a result of this collaboration, Silence and AstraZeneca will work together to develop new and improved approaches for the delivery of siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that they develop together. The successful delivery of siRNA molecules to different tissue sites is critical to realize the exciting potential of siRNA to treat a broad range of diseases.
Silence Therapeutics will retain the right to sign further delivery deals to capture value from its current AtuPLEX delivery technology as well as any improvements to this technology that it generates either independently or as part of this collaboration.